A Remotely Delivered Episodic Future Thinking Intervention to Improve Management of Type 2 Diabetes
NCT ID: NCT03732209
Last Updated: 2024-11-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
59 participants
INTERVENTIONAL
2019-03-01
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MINDD 3: Prediabetes and Delay Discounting
NCT03664726
Mindful Stress Reduction in Diabetes Self-management Education for Veterans
NCT02928952
Technology-assisted Case Management in Adults With Type 2 Diabetes
NCT01373489
Imagine to Remember: Improving Medication Adherence in Pre- and Type 2 Diabetes
NCT04157673
Remotely Delivered Mindfulness-Based Diabetes Education
NCT06312553
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will complete four laboratory-based assessment sessions in which the investigators assess body weight, height, waist and hip circumference, glycemic control (HbA1C), adherence to oral glucose-lowering medication, delay discounting, reinforcing efficacy of food, and blood pressure. These assessments will be completed before the intervention (Week 0), during the intervention (8 weeks), and immediately after the intervention (Week 16), as well after a 2-month post-intervention follow-up (Week 24). The latter three assessments sessions will also include questions to measure participants' perceived effectiveness and ease of use of the intervention. Participants will also complete several remote assessments, including dietary intake and physical activity (during Weeks 0, 8, and 16; via accelerometer), as well as delay discounting and reinforcing efficacy of food (during Weeks 3, 8, and 16).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Episodic future thinking
Participants will generate positive future events and related text cues that will be accessed via an electronic app to engage in episodic future thinking.
Episodic future thinking
Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
Control thinking
Participants will generate non-future-oriented information and related text cues that will be accessed via an electronic app to engage in control thinking..
Control Thinking
Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Episodic future thinking
Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
Control Thinking
Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Poorly controlled type 2 diabetes (HbA1C of 8% or greater)
* Prescribed or recommended oral glucose-lowering medication
Exclusion Criteria
* History of gestational diabetes
* Pregnant or lactating
* Not ambulatory
* Intellectual impairment
* Unmanaged medical or psychiatric disorder
* Abnormal glucose related to medications (e.g, glucocorticoids)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Carilion Clinic
OTHER
University at Buffalo
OTHER
National Institute of Nursing Research (NINR)
NIH
Virginia Polytechnic Institute and State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeffrey Stein
Research Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeff S Stein, PhD
Role: PRINCIPAL_INVESTIGATOR
Virginia Tech Carilion School of Medicine and Research Institute
John W Epling, MD
Role: PRINCIPAL_INVESTIGATOR
Carilion Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fralin Biomedical Research Institute
Roanoke, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2696
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.